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Abstract
Rab GTPases are master regulators of intracellular trafﬁcking and, in recent years, their role in the control
of different aspects of tumour progression has emerged. In the present review, we show that Rab GTPases
are disregulated in many cancers and have central roles in tumour cell migration, invasion, proliferation,
communication with stromal cells and the development of drug resistance. As a consequence, Rab proteins
may be novel potential candidates for the development of anticancer drugs and, in this context, the
preliminary results obtained with an inhibitor of Rab function are also discussed.
Rab proteins as key regulators of
intracellular trafﬁcking
Rab proteins are part of the large Ras superfamily of small
GTPases. There are more than 60 members in humans
and each of them is specifically localized to a subcellular
membrane compartment, ofwhich it controls the intracellular
traffic [1]. Rab proteins cycle between an inactive cytosolic
GDP-bound form and an active membrane-associated GTP-
bound form. When in their GTP-bound form, Rabs recruit
effector proteins that mediate vesicle budding from donor
organelles, transport along microtublules or actin filaments,
and tethering and fusion to acceptor compartments [2]. In
this way, Rab proteins control protein secretion, endocytosis,
recycling and degradation, and are thus widely recognized as
master regulators of intracellular trafficking. The complexity
of combinations between the different Rabs and their
myriad effectors is modulated further by two families of
regulators: the GEFs (guanine-nucleotide-exchange factors),
that promote GTP binding by Rabs, and the GAPs (GTPase-
activating proteins), that trigger Rab GTPase activity and
thus GTP hydrolysis to GDP. The specific localization of
GEFs andGAPs regulate in a precise space- and time-specific
manner the interaction between Rabs and their effectors and,
as a consequence, they control Rab activity.
In recent years, a new role has been emerging for Rab
proteins in the control of tumour progression. Several Rabs
have been found to be deregulated in cancers and many have
been described as central in tumour cell migration, invasion
of the ECM (extracellular matrix), proliferation, signalling to
and from stromal cells, and drug resistance. In the present
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review, we will summarize the current knowledge on the role
that some of these Rabs play in the aforementioned processes.
Rabs are aberrantly expressed in tumours
Several Rabs have been found in transcriptomic studies to
present a deregulated expression in cancer cells compared
with normal tissues, but for many of them a clear function in
the context of cancer progression awaits characterization. For
example, some Rabs such as Rab1b, Rab4b, Rab10, Rab22a
and Rab24 are overexpressed in hepatocellular carcinoma [3].
Rab1a is overexpressed in tongue squamous cell carcinoma
[4], whereas Rab2 is overexpressed in peripheral blood
mononuclear cells from patients with solid tumours [5]
and is associated with lung tumour progression in mouse
[6]. Rab3B is up-regulated in prostate cancer, where it
promotes cancer cell survival [7]. Rab20 is overexpressed in
exocrine pancreatic carcinoma [8] and high levels of Rab31
are associated with worse outcome in breast cancer patients
[9]. Interestingly, recent studies have analysed the expression
profile of miRNAs (microRNAs) in cancer samples and have
found that down-regulation of several miRNAs is associated
with high levels of expression of various Rabs: this is the case
formiR-9 andRab34 [10] and let-7a andRab40c [11] in gastric
carcinoma,miR-451 and Rab14 in non-small lung carcinoma
[12], and has-miR-373 and Rab22a in colon cancer [13].
Conversely, some Rab genes are hypermethylated and thus
down-regulated in tumours, such as those encoding Rab32 in
colon [14] and gastric [15] cancer, and Rab37 in metastatic
lung cancer [16]. Furthermore, Rab38 is down-regulated
in melanoma primary tumours and metastasis compared
withmelanocytes [17]. Interestingly, a recent study in bladder
cancer describes aberrant expression of not only several Rabs
but also some Rab effectors, GAPs and GEFs [18], thus
extending the analysis to Rab-related genes.
The picture emerging from these studies highlights the
possibility that Rab GTPases may play an important role
in cancer progression. Indeed, the contribution of some Rabs
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Figure 1 Rab proteins have multiple functions in tumour cells
The functions of Rab proteins in tumour cells include delivery and recycling of integrins at the front during cell migration,
secretion of proteases to degrade the ECM and invade the surrounding tissues, secretion of exosomes that mediate the
communication with stromal cells, trafﬁcking of receptors and control of their signalling, impact on cell cycle and survival,
and resistance to anticancer drugs.
to tumour progression has been investigated more in detail
and is described in the following sections.
Rabs direct integrin trafﬁcking and cell
migration
A fundamental characteristic of metastatic cells is their
ability to migrate and invade through the ECM to form
metastases in other organs. In a series of well-documented
studies, the family of Rab11 proteins (Rab11a, Rab11b
and Rab25) and their effectors have been demonstrated to
play a key role in the migration of cancer cells through
the modulation of integrin recycling at the migration
front (Figure 1). Rab11a had been described to regulate
α6β4 integrin transport at the cell surface during hypoxia-
stimulated migration in breast cancer cells [19]. Rab25 is
overexpressed in human ovarian cancers, where it correlates
with poor prognosis, and increases cell survival in vitro
and tumorigenesis in vivo [20]. In seminal works from Jim
Norman’s group, Rab25 has been shown to associate with
α5β1 integrin and promote its delivery at the pseudopodial
tip of invading cells, thus driving cell migration in a three-
dimensional environment [21]. Also, Rab25 collaborates with
CLIC3 (chloride intracellular channel protein 3) to recycle
integrins from late compartment to the back of migrating
cells, a process necessary for the release of the cell rear
during invasion [22]. Interestingly, the same group has also
shown that the recycling of α5β1 integrin is coupled to the
recycling of EGFR (epidermal growth factor receptor) via
the interaction with RCP (Rab-coupling protein), and this
results in an increase in EGFR signalling to the survival factor
Akt [23]. RCP is an effector of Rab11 and has been described
as an oncogene that promotes breast cancer transformation
[24]. Furthermore, RCP-mediated recycling and signalling
of both integrin and EGFR are located downstream of a
mutant form of p53 that drives an increase in cancer cell
invasiveness [25]. In this way, metastatic cells integrate and
co-ordinate signalling pathways important for migration
and proliferation throughRab-mediated vesicular trafficking.
Of note, although Rab25 has been described clearly as an
oncogene in certain types of cancer, it has also been shown
to act as a tumour suppressor in others, such as colorectal
cancers [26,27] and triple-negative breast cancers [28,29]. So
the exact function of Rab25 in tumour progression is likely to
be context-dependent. Another Rab involved in the control
of integrin trafficking isRab21.Rab21 binds toα integrins in a
GTP-dependent fashion and its level of expression correlates
with integrin-mediated adhesion andmotility in breast cancer
cells [30]. Integrin internalization is also mediated by Rab5
and depletion of Rab5 reduces migration in vitro and
tumour metastasis in neuroblastoma, downstream of caspase
8 signalling [31]. Furthermore, Rab5a expression is associated
with higher-grade and lymph nodemetastasis in breast cancer
patients [32], and it is overexpressed in cervical cancer, where
again it promotes cell motility and invasion [33], and in
hepatocellular carcinoma, where a dominant-negativemutant
decreases cell migration [34].
Rabs promote protease secretion and cell
invasion
Tumour cells secrete a variety of proteases, including MMPs
(matrix metalloproteinases), which help the cells to breach
the basal membrane and the ECM and migrate to distant
organs. Some Rabs have been described to play a role in the
context of MMP secretion or activation (Figure 1). In breast
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cancer cells, for instance, Rab8 contributes to cell invasiveness
by promoting the secretion of MT1-MMP (membrane-type
1 MMP) at peripheral invasive structures [35]. Rab7 has
also been recently described as contributing to MT1-MMP
secretion and a dominant-negative mutant of Rab7 impairs
both cell migration and invasion [36]. Rab27b, which is
associated with lymph node metastasis and differentiation
grade in ER (oestrogen receptor)-positive human breast
cancer patients, induces invasive growth of breast cancer
cells via the secretion of Hsp90α (heat-shock protein 90α),
which is required for the extracellular activation of MMP2
[37]. Rab27a is overexpressed in lymph node metastases
in breast cancer cells [38] and in primary hepatocellular
carcinoma [39], it has been suggested to promote cell
invasiveness [40] and we recently observed that it is required
for secretion of MMP9 by mouse mammary carcinoma cells
[41]. Another protease important for the modification of
the tumour microenvironment is procathepsin-L and its
secretion is controlled by Rab4 [42]. Indeed, overexpression
of Rab4 in melanoma causes an increase in tumour mass,
whereas depletion of Rab4 induces a reduction in tumour
volume [42].
Rabs contribute to tumour–stromal cell
communication and the modiﬁcation of
the tumour microenvironment
In recent years, the rising importance of stromal cells in the
creation of a tumour microenvironment favourable to cancer
cell growth and metastasis has emerged. Important actors in
this process are CAFs (cancer-associated fibroblasts) [43],
which, among other functions, remodel the ECM. In this
context, Rab21 has been shown to promote integrin
accumulation at the plasma membrane and actomyosin con-
tractility in CAFs, which results in collagen contraction and
allows the invasion of squamous cell carcinoma through the
CAF-modified matrix [44]. Other important mediators in
intercellular communication between cancerous and stromal
cells are tumour-derived microvescicles and exosomes [45]
(Figure 1). In this context, Rab27a was shown to be required
for secretion of exosomes by HeLa cells [46]. In vivo,
Rab27a inhibition in melanoma cell lines reduced primary
tumour growth and formation of lung metastases: this
anti-tumour effect was due to a combination of impaired
secretion of pro-angiogenic factors such as PlGF (placental
growth factor), and decreased secretion of exosomes that
‘educate’ and recruit bone-marrow-derived cells to create
a pro-metastatic niche [47]. Of note, Rab27a had been
identified previously as a driver gene in melanoma [48]. In
a similar manner, combined Rab27a-dependent secretion of
MMP9 and exosomes contributes to the mobilization of a
pro-tumoral neutrophil population and supports growth of
a mouse mammary tumour and its metastasis to lungs [41].
Rabs affect cell-cycle progression
The aberrant expression of some Rabs has been shown
to affect cell-cycle progression. One example is Rab27b:
its overexpression promotes cell-cycle progression and
proliferation in the breast cancer cell line MCF-7 and this
is dependent on its GTP-loaded active state [37]. Another
Rab described in this context is Rab6c, which is localized
to the centrosome and whose overexpression results in G1-
phase arrest and whose depletion generates tetraploid cells
[49]. Furthermore, Rab21-mediated trafficking of integrins
at the cleavage furrow is required for cytokinesis and, as a
consequence, cells depleted of Rab21 present multinuclei and
genomic instability [50].
Rab23 antagonizes the Shh (Sonic
Hedgehog) pathway
The morphogenic Shh pathway is essential in the embryonic
dorsoventral development and is deregulated in many
cancers. Rab23 was first identified as an antagonist of
the Shh signalling pathway [51] and recently it has been
shown to interact in its GTP-bound form with Su(Fu) and
thus inhibit the Gli transcription factor that is normally
activated downstreamof Shh signalling [52].However, Rab23
is overexpressed in diffuse-type gastric cancer, where it
promotes cell invasion [53], and in hepatocellular carcinoma,
where it supports cell growth [54], so its role in tumour
progression might also be Shh-independent.
Rabs are involved in resistance to
anticancer drugs
MDR (multidrug resistance) in human cancers is often
associated with the overexpression of P-gp (P-glycoprotein),
a large transmembrane protein localized at the plasma
membrane that extrudes anticancer drugs and thus decreases
their concentration, and toxicity, inside the cells [55].
The recycling protein Rab4 interacts with P-gp, but it is
underexpressed in MDR cells [56]. However, when Rab4
is overexpressed, it decreases P-gp levels at the plasma
membrane, thus increasing drug sensitivity in MDR cells
[56] (Figure 1). Similarly, Rab6c is underexpressed in
MDR cells and its overexpression induces the intracellular
accumulation of several anticancer drugs, although the
mechanism underlying this phenotype has not yet been
established [57]. Another Rab involved in resistance to a
chemotherapeutic drug is the secretory Rab8: cancer cells
resistant to the platinum compound cisplatin have high
levels of Rab8 and overexpression of Rab8 in sensitive
cells enhances resistance to cisplatin, possibly by increasing
the secretion of the cisplatin-resistance-associated protein
TMEM205 (transmembrane protein 205), with which it co-
localizes [58].
A role for GAPs in cancer
As mentioned above, the activity of Rab proteins is regulated
by GEFs and GAPs, and some of them may well play a
role in cancer. PRC17 (prostate cancer gene 17) (TBC1D3A)
is a GAP for Rab5, it is overexpressed in metastatic
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prostate cancer and its overexpression transforms NIH 3T3
fibroblasts [59]. Another GAP for Rab5 implicated in cell
transformation is the regulatory subunit of class I PI3K
(phosphoinositide 3-kinase) p85α: if p85α is impaired in
its GAP function, it induces loss of contact inhibition,
growth in soft agar and tumour formation in nude mice,
owing to disrupted regulation of PDGFR (platelet-derived
growth factor receptor) trafficking and increased downstream
signalling to Akt [60]. Another GAP recently described in
cancer is TBC1D7, a GAP for Rab17: it is overexpressed
in lung cancer, where it is associated with poor prognosis,
and promotes cell growth [61]. Also, TBC1D16 has been
identified using a bioinformatic approach as a driver gene for
melanoma and its depletion reduces melanoma cell growth
[48]. However, its substrate Rab is not yet known.
Rabs as therapeutic targets
Since Rab proteins are implicated in multiple aspects of
tumour progression, they might represent new targets
for anticancer therapies. Although no Rab-specific drug
has been developed to date, it is important to mention
encouraging results obtained with inhibitors of RabG-
GTase (Rab geranylgeranyltransferase). All Rabs are post-
translationally modified mostly by the addition of two
geranylgeranyl groups at their C-termini by RabGGTase
and this modification is essential for the association of Rab
proteins tomembranes. The gunmetalmousemodel, inwhich
Rabprenylation is severely reducedowing to an 80%decrease
in RabGGTase activity, presents only hypopigmentation
and altered platelet biogenesis, showing that a decrease
in Rab prenylation would be generally well tolerated [62].
RabGGTase is overexpressed in some tumours and some
farnesyltransferase inhibitors that have a pro-apoptotic
effect indeed target RabGGTase and can be mimicked by
depletion ofRabGGTase [63]. A biphosphonate derivative, 3-
PEHPC [3-(3-pyridyl)-2-hydroxy-2-phosphonopropanoic
acid], which is highly specific for RabGGTase, has an anti-
resorptive activity in osteoclasts [64], induces apoptosis of
human myeloma cells in vitro [65] and prevents bone disease
in vivo in a mouse model [66]. Furthermore, it inhibits
metastatic cell invasion in vitro [67] and reduces skeletal
tumour growth in vivo [68]. These findings highlight the
potentiality of Rab inhibition as a therapeutic approach.
Concluding remarks
Mutations in some Rabs or in regulators of the Rab
GTP/GDP cycle had been identified as causative of some
severe complex hereditary diseases [69]. However, the
potential role of Rab proteins in the context of tumour
progression has only begun to emerge in recent years. As
presented above, some functions for Rab GTPases in cancer
development have now been elucidated and the emerging
picture points to the importance of intracellular trafficking as
a co-ordinator of the cross-talk between signalling pathways
promoting proliferation, migration and invasion. Also, Rabs
have been shown to direct the communication between
cancerous and stromal cells, and are thus able to modulate
the creation of a metastatic niche favourable to tumour
growth, an emerging concept that is attracting much interest
as a therapeutic target. Although inhibitors of specific Rab
proteins have not yet been developed, they could represent a
potential tool as novel anticancer drugs in the years to come.
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